Skip to main content
Premium Trial:

Request an Annual Quote

NantHealth Lands $137.5M in Financing to Extend Debt Maturity Date

NEW YORK – NantHealth said Wednesday that it has reached agreements for $137.5 million in new financing that will extend the maturity date of existing debt instruments to 2026. The transaction will close no later than April 27.

Under the deal, El Segundo, California-based NantHealth is issuing new senior unsecured convertible notes with a 2026 maturity to existing investors Highbridge Capital Management and Nant Capital. The latter is an investment vehicle of NantHealth's founder and CEO, Patrick Soon-Shiong, who is also the firm's largest shareholder.

The firm plans to use the proceeds of the new 2026 notes to retire existing convertible notes that are due in December, as well as for operating capital.

The 2026 notes will carry an interest rate of 4.5 percent, payable semiannually, though NantHealth said that investors will be able to convert the instruments to company stock. Terms will be disclosed in a future filing with the US Securities and Exchange Commission.

Additionally, Highbridge and Cambridge Equities — another Soon-Shiong company — have each agreed to convert $5 million of their investments in the 2021 notes into NantHealth common stock as of Wednesday. The stock closed Tuesday at $2.96 per share.

"Not only does this financing address the upcoming maturity of our 2021 notes, but importantly provides us with the resources to invest in our established businesses, NaviNet and Eviti, and accelerate the expansion of our recently acquired OpenNMS business," NantHealth Chief Operating Officer Ron Louks said in a statement.

"Last year, NantHealth made a strategic decision to expand beyond healthcare by providing enterprise solutions to help businesses in other industries," said Jonathan Segal, co-chief investment officer of Highbridge, referring to the July 2020 acquisition of OpenNMS Group, an open-source network management company. "We believe this financing will help NantHealth achieve this goal and continue further product expansion."

NantHealth has not drawn on a $100 million line of credit offered by Nant Capital in 2018. The firm has reported just one profitable quarter in its history, the first quarter of 2020.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more